** Shares of life sciences company Pacific Biosciences PACB.O fall 2% to $1.45 premarket
** It reported Q4 revenue of $39.2 million late on Thursday, a decrease of 33% from the prior year and missing estimates of $40.2 million, according to data compiled by LSEG
** The company forecast 2025 revenue to range between $155 million and $170 million, versus an estimate of $172.4 million
** The forecast includes factors such as the recent announcement to cap National Institutes of Health funding, it says
** "We're in the early innings of FY25 and uncertainties remain high, making the error bars wide this year. Debates likely center around the outlook and PACB's ability to return to growth, and after a year of misses/guide downs, execution will be key this year" - brokerage Stephens
** The stock fell 81.4% in 2024
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.